证券日报网讯8月7日晚间，华大智造发布公告称，公司于2025年8月6日召开2025年第一次职工代表大 会，经全体与会职工代表表决，同意选举谢伟伟女士为公司第二届董事会职工代表董事，任期自公司职 工代表大会选举之日起至公司第二届董事会任期届满之日止。 ...

二、 董事辞任对公司的影响 朱岩梅女士辞任未导致公司董事会成员人数低于法定人数，不会影响公司董 事会的正常运行，其职务变动不会对公司正常经营活动产生不利影响。 证券代码：688114 证券简称：华大智造 公告编号：2025-048 深圳华大智造科技股份有限公司 关于公司董事辞任暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 深圳华大智造科技股份有限公司（以下简称"公司"）董事会于近日收到公 司董事朱岩梅女士的《辞任报告》，朱岩梅女士因个人原因申请辞去公司董事职 务。根据《中华人民共和国公司法》（以下简称《公司法》）、《公司章程》及有关 法律法规的规定，朱岩梅女士的辞任申请自《辞任报告》送达公司董事会时生效， 朱岩梅女士辞任未导致公司董事会成员人数低于法定人数，不会影响公司董事会 的正常运行，其职务变动不会对公司正常经营活动产生不利影响。 公司于 2025 年 8 月 6 日召开 2025 年第一次职工代表大会，选举谢伟伟女士 为公司第二届董事会职工代表董事，谢伟伟女士与公司第二届董事会 ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 1.69% as of August 7, 2025, with mixed performance among constituent stocks [1] - Huada Zhizao led the gains with an increase of 4.42%, while Yuyuan Pharmaceutical and others experienced declines [1][5] - The market for the Sci-Tech Innovation Medical ETF managed by Harvest saw a turnover of 27.9% and a transaction volume of 65.88 million yuan, indicating active trading [3] Group 2 - As of August 6, 2025, the Sci-Tech Innovation Medical ETF reached a new high in scale at 237 million yuan, ranking first among comparable funds [3] - The ETF saw a net inflow of 2.96 million yuan recently, with a total of 17.65 million yuan accumulated over the last five trading days [3] - The ETF's net value increased by 49.39% over the past year, with the highest monthly return recorded at 23.29% since its inception [3] Group 3 - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index accounted for 49.14% of the index, with leading stocks including United Imaging Healthcare and BeiGene [3] - Minsheng Securities believes that domestic medical insurance policy support and overseas value recognition will sustain the ongoing trend of Chinese innovative drugs [5] - China has become a core procurement area for global trading, with traditional pharmaceutical companies accelerating their innovation and international expansion [5]

8月7日早盘，医疗板块涨势又起，A股最大医疗ETF（512170）盘初冲高2%，成交额快速突破4亿元。 成份股方面，医疗器械概念股领涨，福瑞股份一度涨近8%，华大智造、英科医疗涨超6%。CXO概念普 跌，药明康德、昭衍新药跌逾1%。 | | | 分时 多日 1分 5分 15分 30分 60分 · | | | | | F9 盘前盘后 露加 九粒 画纸 工具 @ 0 | | 医疗ETF ① | | 512170 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 512170(医疗ETF) 10:10 价 0.372 涨跌 0.004(1.09%) 均价 0.372 服交量 9404 IOPV | | | | | | | | 087 | | | | | | | | 1.98% | 0.372 | | +0.004 +1.09% | | | | | | | | | | | | SSE CNY 10:10:58 文易中 | 通的方面开 | | 0.372 | | | | | | | | 0.99 ...

Market Performance - The CSI Guangdong-Hong Kong-Macao Greater Bay Area Development Theme Index (931000) increased by 0.67% as of August 7, 2025 [2] - Notable stock performances include BGI Genomics (688114) up by 6.49%, Industrial Fulian (601138) up by 5.95%, and Luxshare Precision (002475) up by 5.50% [2] - The Greater Bay Area ETF (512970) rose by 0.46%, marking its third consecutive increase, with the latest price at 1.3 yuan [2] Government Initiatives - Hong Kong Chief Executive John Lee led a government delegation to Macau on August 5, 2025, to discuss cooperation and high-quality development in the Greater Bay Area [3] - The construction of the Hengqin Guangdong-Macao Deep Cooperation Zone is highlighted as a significant initiative to enhance the "One Country, Two Systems" practice, benefiting Macau's long-term stability and integration into national development [3] ETF Performance Metrics - The Greater Bay Area ETF's net value increased by 33.03% over the past year as of August 6, 2025 [4] - The ETF achieved a maximum monthly return of 21.99% since its inception, with an average monthly return of 5.14% during rising months [4] - The ETF's management fee is 0.15%, and the custody fee is 0.05% [4] Index Composition - The CSI Guangdong-Hong Kong-Macao Greater Bay Area Development Theme Index reflects the performance of listed companies benefiting from the Greater Bay Area's development [5] - As of July 31, 2025, the top ten weighted stocks in the index include Ping An Insurance (601318), BYD (002594), and China Merchants Bank (600036), collectively accounting for 50.37% of the index [5]

Core Viewpoint - The company has approved the use of idle self-owned funds and temporarily idle raised funds for cash management, ensuring that it does not affect the implementation of fundraising projects and the normal development of its main business [1][3]. Group 1: Cash Management Approval - The company plans to use up to RMB 20 billion of idle self-owned funds and up to RMB 17 billion of temporarily idle raised funds for cash management, focusing on high-security and high-liquidity deposit products or capital-protected products [1]. - The approved cash management will be valid for 12 months from the date of the board's approval, allowing for the funds to be used in a rolling manner within the specified limits [1]. Group 2: Special Settlement Account - The company has recently opened a special settlement account for cash management of raised funds, which will only be used for the settlement of temporarily idle raised funds [2]. - The account will be closed promptly when cash management products mature and there are no further purchase plans [2]. Group 3: Risk Control Measures - The company will strictly adhere to relevant regulations and internal policies when conducting cash management activities, with the finance department monitoring investment risks [3]. - The audit department and supervisory board have the authority to supervise and inspect the use of funds, and may hire professional institutions for auditing if necessary [3]. Group 4: Impact on the Company - The use of idle raised funds for cash management is expected to enhance fund utilization efficiency and generate investment returns, ultimately benefiting the company's performance and providing greater returns for shareholders [3].

Group 1 - The stock price of BGI Genomics is reported at 67.76 yuan, down 1.15% from the previous trading day, with an intraday high of 69.35 yuan and a low of 67.19 yuan, and a trading volume of 2.11 billion yuan [1] - BGI Genomics' main business includes the research, development, production, and sales of instruments and consumables related to life sciences and healthcare, covering products such as gene sequencers and laboratory automation equipment [1] - The company has recently opened a special settlement account for cash management of raised funds, planning to use up to 2 billion yuan of idle self-owned funds and 1.7 billion yuan of idle raised funds for cash management, focusing on purchasing safe and liquid deposit-type or capital-protected products [1]

Core Viewpoint - The company has approved the use of idle self-owned funds and raised funds for cash management, ensuring that it does not affect the implementation of fundraising projects and the normal development of its main business [2][5]. Group 1: Cash Management Account - The company has recently opened a special settlement account for cash management of raised funds, which will be used exclusively for temporarily idle raised funds [3]. - The account will be closed promptly when cash management products mature and there are no further purchase plans [3]. Group 2: Risk Control Measures - The company will strictly adhere to relevant regulations and internal policies when conducting cash management activities, with the finance department monitoring investment risks [4]. - The audit department and supervisory board have the authority to supervise and inspect the use of funds, and may hire professional institutions for auditing if necessary [4]. Group 3: Impact on the Company - The use of idle raised funds for cash management is expected to enhance fund utilization efficiency and generate investment returns, ultimately benefiting the company's performance and shareholders [5].

Core Points - The company, BGI Genomics, announced plans to utilize idle funds for cash management, with a maximum of RMB 20 billion from its own funds and RMB 17 billion from raised funds [2] Group 1 - The second board meeting and supervisory board meeting will be held on April 24, 2025, to review the cash management proposal [2] - The funds will be used to purchase high-security and high-liquidity deposit products or capital-protected products [2] - The approved fund usage is valid for 12 months from the date of the board's approval, allowing for rolling use of the funds within the specified limits [2]

证券代码：688114 证券简称：华大智造 公告编号：2025-047 深圳华大智造科技股份有限公司 关于开立募集资金现金管理专用结算账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳华大智造科技股份有限公司（以下简称"公司"或"华大智造"）于 2025 年 4 月 24 日召开第二届董事会第十二次会议、第二届监事会第十二次会议， 审议通过了《关于使用部分暂时闲置自有资金及募集资金进行现金管理的议案》， 同意公司在确保不影响公司募投项目建设实施、募集资金使用计划和保证募集资 金安全且不影响公司主营业务的正常发展，并确保公司经营资金需求的前提下， 使用最高额不超过人民币 20 亿元（含本数）的闲置自有资金及最高额不超过人 民币 17 亿元（含本数）的暂时闲置募集资金进行现金管理，用于购买安全性高、 流动性好的存款类产品或保本型产品，上述额度自公司董事会审议通过之日起 12 个月内有效，在前述额度和期限范围内，资金可循环滚动使用。具体内容详 见公司于上海证券交易所网站（www.sse.com.cn）披露的《关于使 ...